Help by Factory against swien flu

Workers at the GlaxoSmithKline (GSK) factory in Montrose are getting ready to restart production of an essential component of a drug to treat swine flu.

The plant will restart manufacturing zanamivir, the active ingredient in Relenza, in the next few weeks.
Production will last about six months and is designed to replace supplies which are currently being used up because of the swine flu scare.
GSK has said it plans to increase production levels of Relenza.
By the end of the year, it expects to raise its annual production capacity to 190 million treatment courses.
The previous maximum capacity was 60 million treatment courses.
Relenza, which has previously been used in the treatment of bird flu, is an alternative to Tamiflu.
Tamiflu is the drug which has been most widely used in the UK when treating swine flu.